Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.46 USD
+0.01 (1.28%)
Updated May 9, 2024 03:59 PM ET
After-Market: $0.46 0.00 (0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Redhill Biopharma Ltd. [RDHL]
Reports for Purchase
Showing records 21 - 40 ( 228 total )
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Top-Line Miss, Bottom-Line In Line; Positive 1Q21 Sales Trends; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
A Trifecta of Products With a Pipeline Punch; Initiating at Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
3Q20 Recap - COVID Continues to Present Challenges and Opportunities
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Rapid COVID-19 Ph II/III programme progress
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
First quarter with significant sales; Cosmo deal
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
COVID-19 Program Gaining Focus in Coming Months
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Rapid progress with COVID-19 programme
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Movantik acquisition completed; sales booked
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
1Q20 Recap - Opportunities and Threats from COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S